Clínic Barcelona
Research

A European study in people with the participation of Clínic-IDIBAPS shows that treatment with the drug Abatacept reduces the risk of developing rheumatoid arthritis

Published in the journal The Lancet, the study presents the results of Abatacept, a drug that modulates the activation of T cells, which play a key role in the progression of the disease. This trial has been carried out in 14 European hospitals (11 German, two Spanish and one Czech) and Juan D. Cañete, who works for Hospital Clínic Barcelona’s Rheumatology Service and is a researcher in IDIBAPS’ Inflammatory Joint Diseases IJDS) research group. 

Juan D. Cañete

Juan D. Cañete

Related contents
Keep reading about:

Related news